At Coherus BioSciences, we’re committed to ensuring patient access to biologics. That’s why we’ve developed Coherus COMPLETE, a program offering comprehensive patient access and reimbursement support services.

Overview of Coherus COMPLETE services

REIMBURSEMENT SUPPORT

Coherus COMPLETE Patient Access Specialists assist with:

  • Product-specific benefits verification and coverage assessment
  • Comprehensive Prior Authorization (PA) services
  • Coding and billing support
  • Claims and PA appeals support
  • Alternative funding support

ACCESS SUPPORT SERVICES & PROGRAMS

  • The Coherus COMPLETE Provider Portal
  • Product Replacement Program
  • Field Reimbursement Specialists

PATIENT SUPPORT SERVICES & PROGRAMS

  • The Coherus COMPLETE Co-Pay Assistance Program
  • Patient Assistance Program (PAP)

Coherus COMPLETE Co-Pay Assistance Program

  • The Coherus COMPLETE Co-Pay Assistance Program reduces out-of-pocket costs for patients who are commercially insured
    • $0 out-of-pocket patient cost per UDENYCA dose*

*Patients covered under Medicare, Medicaid, or any federal or state-funded program will not be eligible for the Coherus COMPLETE Co-Pay Assistance Program.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells or hematopoietic stem cell transplantation.

Please see Full Prescribing Information, Patient Information, and Instructions for Use.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYC if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells or hematopoietic stem cell transplantation.

Please see Full Prescribing Information, Patient Information, and Instructions for Use.